Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Developing User Personas to Aid in the Design of a User-Centered Natural Product-Drug Interaction Information Resource for Researchers.

Boyce RD, Ragueneau-Majlessi I, Yu J, Tay-Sontheimer J, Kinsella C, Chou E, Brochhausen M, Judkins J, Gufford BT, Pinkleton BE, Cooney R, Paine MF, McCune JS.

AMIA Annu Symp Proc. 2018 Dec 5;2018:279-287. eCollection 2018.

2.

Past, Present, and Future of Drug-Drug Interactions.

Levy RH, Ragueneau-Majlessi I.

Clin Pharmacol Ther. 2019 Jun;105(6):1286-1288. doi: 10.1002/cpt.1349. Epub 2019 Feb 17. No abstract available.

PMID:
30773619
3.

Drug-Drug Interactions of Infectious Disease Treatments in Low-Income Countries: A Neglected Topic?

McFeely SJ, Yu J, Zhao P, Hershenson S, Kern S, Ragueneau-Majlessi I, Hartman D.

Clin Pharmacol Ther. 2019 Jun;105(6):1378-1385. doi: 10.1002/cpt.1397. Epub 2019 Mar 21.

4.

Identification and Evaluation of Clinical Substrates of Organic Anion Transporting Polypeptides 1B1 and 1B3.

McFeely SJ, Ritchie TK, Yu J, Nordmark A, Levy RH, Ragueneau-Majlessi I.

Clin Transl Sci. 2019 Jul;12(4):379-387. doi: 10.1111/cts.12623. Epub 2019 Mar 12.

5.

Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017.

Yu J, Petrie ID, Levy RH, Ragueneau-Majlessi I.

Drug Metab Dispos. 2019 Feb;47(2):135-144. doi: 10.1124/dmd.118.084905. Epub 2018 Nov 15. Review.

PMID:
30442649
6.

Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between 2013 and 2016.

Yu J, Zhou Z, Tay-Sontheimer J, Levy RH, Ragueneau-Majlessi I.

Drug Metab Dispos. 2018 Jun;46(6):835-845. doi: 10.1124/dmd.117.078691. Epub 2018 Mar 23.

PMID:
29572333
7.

Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions.

Huang W, Nakano M, Sager J, Ragueneau-Majlessi I, Isoherranen N.

Drug Metab Dispos. 2017 Nov;45(11):1156-1165. doi: 10.1124/dmd.117.076455. Epub 2017 Aug 31.

8.

Intestinal Drug Interactions Mediated by OATPs: A Systematic Review of Preclinical and Clinical Findings.

Yu J, Zhou Z, Tay-Sontheimer J, Levy RH, Ragueneau-Majlessi I.

J Pharm Sci. 2017 Sep;106(9):2312-2325. doi: 10.1016/j.xphs.2017.04.004. Epub 2017 Apr 13. Review.

PMID:
28414144
9.

What Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug Interaction Data for Drugs Approved by the US FDA in 2015.

Yu J, Zhou Z, Owens KH, Ritchie TK, Ragueneau-Majlessi I.

Drug Metab Dispos. 2017 Jan;45(1):86-108. Epub 2016 Nov 7. Review.

PMID:
27821435
10.

Investigating ABCB1-Mediated Drug-Drug Interactions: Considerations for In vitro and In vivo Assay Design.

Sáfár Z, Vaskó B, Ritchie TK, Imre G, Mogyorósi K, Erdő F, Rajnai Z, Fekete Z, Szerémy P, Muka L, Zolnerciks JK, Herédi-Szabó K, Ragueneau-Majlessi I, Krajcsi P.

Curr Drug Metab. 2016;17(5):430-55. Review.

PMID:
26728264
11.

Key Findings from Preclinical and Clinical Drug Interaction Studies Presented in New Drug and Biological License Applications Approved by the Food and Drug Administration in 2014.

Yu J, Ritchie TK, Zhou Z, Ragueneau-Majlessi I.

Drug Metab Dispos. 2016 Jan;44(1):83-101. doi: 10.1124/dmd.115.066720. Epub 2015 Sep 30. Review.

PMID:
26424199
12.

Organ Impairment-Drug-Drug Interaction Database: A Tool for Evaluating the Impact of Renal or Hepatic Impairment and Pharmacologic Inhibition on the Systemic Exposure of Drugs.

Yeung CK, Yoshida K, Kusama M, Zhang H, Ragueneau-Majlessi I, Argon S, Li L, Chang P, Le CD, Zhao P, Zhang L, Sugiyama Y, Huang SM.

CPT Pharmacometrics Syst Pharmacol. 2015 Aug;4(8):489-94. doi: 10.1002/psp4.55. Epub 2015 Jul 14.

13.

Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.

Sager JE, Yu J, Ragueneau-Majlessi I, Isoherranen N.

Drug Metab Dispos. 2015 Nov;43(11):1823-37. doi: 10.1124/dmd.115.065920. Epub 2015 Aug 21. Review.

14.

Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design.

Lee CA, O'Connor MA, Ritchie TK, Galetin A, Cook JA, Ragueneau-Majlessi I, Ellens H, Feng B, Taub ME, Paine MF, Polli JW, Ware JA, Zamek-Gliszczynski MJ.

Drug Metab Dispos. 2015 Apr;43(4):490-509. doi: 10.1124/dmd.114.062174. Epub 2015 Jan 13. Review.

PMID:
25587128
15.

Drug disposition and drug-drug interaction data in 2013 FDA new drug applications: a systematic review.

Yu J, Ritchie TK, Mulgaonkar A, Ragueneau-Majlessi I.

Drug Metab Dispos. 2014 Dec;42(12):1991-2001. doi: 10.1124/dmd.114.060392. Epub 2014 Sep 30. Review.

PMID:
25271211
16.

Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug.

Vieira ML, Kirby B, Ragueneau-Majlessi I, Galetin A, Chien JY, Einolf HJ, Fahmi OA, Fischer V, Fretland A, Grime K, Hall SD, Higgs R, Plowchalk D, Riley R, Seibert E, Skordos K, Snoeys J, Venkatakrishnan K, Waterhouse T, Obach RS, Berglund EG, Zhang L, Zhao P, Reynolds KS, Huang SM.

Clin Pharmacol Ther. 2014 Feb;95(2):189-98. doi: 10.1038/clpt.2013.187. Epub 2013 Sep 18.

PMID:
24048277
17.

Application of receiver operating characteristic analysis to refine the prediction of potential digoxin drug interactions.

Ellens H, Deng S, Coleman J, Bentz J, Taub ME, Ragueneau-Majlessi I, Chung SP, Herédi-Szabó K, Neuhoff S, Palm J, Balimane P, Zhang L, Jamei M, Hanna I, O'Connor M, Bednarczyk D, Forsgard M, Chu X, Funk C, Guo A, Hillgren KM, Li L, Pak AY, Perloff ES, Rajaraman G, Salphati L, Taur JS, Weitz D, Wortelboer HM, Xia CQ, Xiao G, Yamagata T, Lee CA.

Drug Metab Dispos. 2013 Jul;41(7):1367-74. doi: 10.1124/dmd.112.050542. Epub 2013 Apr 25.

18.

Predicting substrates of the human breast cancer resistance protein using a support vector machine method.

Hazai E, Hazai I, Ragueneau-Majlessi I, Chung SP, Bikadi Z, Mao Q.

BMC Bioinformatics. 2013 Apr 15;14:130. doi: 10.1186/1471-2105-14-130.

19.

Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data.

Isoherranen N, Lutz JD, Chung SP, Hachad H, Levy RH, Ragueneau-Majlessi I.

Chem Res Toxicol. 2012 Nov 19;25(11):2285-300. doi: 10.1021/tx300192g. Epub 2012 Sep 27. Review.

20.

e-PKGene: a knowledge-based research tool for analysing the impact of genetics on drug exposure.

Hachad H, Overby CL, Argon S, Yeung CK, Ragueneau-Majlessi I, Levy RH.

Hum Genomics. 2011 Jul;5(5):506-15. Review.

21.
22.

Interaction between clopidogrel and proton pump inhibitors: hypothesis to explain multifactorial CYP2C19 inhibition.

Zhang H, Ragueneau-Majlessi I, Levy RH.

Drug Metab Lett. 2009 Dec;3(4):287-9.

PMID:
19995331
23.

Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study.

Zhao P, Ragueneau-Majlessi I, Zhang L, Strong JM, Reynolds KS, Levy RH, Thummel KE, Huang SM.

J Clin Pharmacol. 2009 Mar;49(3):351-9. doi: 10.1177/0091270008331196.

PMID:
19246732
24.

Pharmacokinetics, safety, and tolerability of the new antiepileptic carisbamate in the elderly.

Levy R, Ragueneau-Majlessi I, Solanki B, Zannikos P, Yao C, Novak G.

Epilepsy Res. 2008 Mar;79(1):22-30. doi: 10.1016/j.eplepsyres.2007.12.013. Epub 2008 Feb 14.

PMID:
18280116
25.

Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis.

Ragueneau-Majlessi I, Boulenc X, Rauch C, Hachad H, Levy RH.

Curr Drug Metab. 2007 Dec;8(8):810-4.

PMID:
18220561
26.

Prediction of maximum exposure in poor metabolizers following inhibition of nonpolymorphic pathways.

Collins C, Levy R, Ragueneau-Majlessi I, Hachad H.

Curr Drug Metab. 2006 Apr;7(3):295-9.

PMID:
16611023
27.

Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy.

Ragueneau-Majlessi I, Levy RH, Brodie M, Smith D, Shah J, Grundy JS.

Clin Pharmacokinet. 2005;44(5):517-23.

PMID:
15871637
28.

Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy.

Levy RH, Ragueneau-Majlessi I, Brodie MJ, Smith DF, Shah J, Pan WJ.

Ther Drug Monit. 2005 Apr;27(2):193-8.

PMID:
15795651
29.

Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients.

Ragueneau-Majlessi I, Levy RH, Bergen D, Garnett W, Rosenfeld W, Mather G, Shah J, Grundy JS.

Epilepsy Res. 2004 Nov;62(1):1-11.

PMID:
15519127
30.

Lack of a clinically significant effect of zonisamide on phenytoin steady-state pharmacokinetics in patients with epilepsy.

Levy RH, Ragueneau-Majlessi I, Garnett WR, Schmerler M, Rosenfeld W, Shah J, Pan WJ.

J Clin Pharmacol. 2004 Nov;44(11):1230-4.

PMID:
15496640
31.
32.

Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women.

Ragueneau-Majlessi I, Levy RH, Janik F.

Epilepsia. 2002 Jul;43(7):697-702.

33.

New antiepileptic drugs: review on drug interactions.

Hachad H, Ragueneau-Majlessi I, Levy RH.

Ther Drug Monit. 2002 Feb;24(1):91-103. Review.

PMID:
11805729
34.

Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin.

Ragueneau-Majlessi I, Levy RH, Meyerhoff C.

Epilepsy Res. 2001 Nov;47(1-2):55-63.

PMID:
11673021

Supplemental Content

Loading ...
Support Center